drugset / Trial / NCT03235050

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050

Phase 2 Completed 834 enrolled AstraZeneca MedImmune LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382

Timeline

Start
2017-08-02
Primary completion
2018-05-03
Completion
2019-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide 100 ug Subcutaneous
Subject Cotadutide Peptide 200 ug Subcutaneous
Subject Cotadutide Peptide 300 ug Subcutaneous
Comparator Liraglutide Peptide 1.8 mg Subcutaneous